These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11196 related articles for article (PubMed ID: 1396075)

  • 21. [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
    Zhou J; Xu B; Zhou A
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):460-2. PubMed ID: 10920884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin].
    Xu B; Zhou J; Zhou A
    Zhonghua Zhong Liu Za Zhi; 1997 Sep; 19(5):358-61. PubMed ID: 10920916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
    Harousseau JL; Zittoun R; Bonneterre J; Hedouin M; Ouvry J
    Bull Cancer; 2000 Jun; 87(6):491-7. PubMed ID: 10903790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
    Marty M; Kleisbauer JP; Fournel P; Vergnenegre A; Carles P; Loria-Kanza Y; Simonetta C; de Bruijn KM
    Anticancer Drugs; 1995 Feb; 6 Suppl 1():15-21. PubMed ID: 7749165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
    Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
    J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
    Suminaga M; Furue H; Taguchi T; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1879-90. PubMed ID: 1387774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
    Beck TM
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
    J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
    Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1347-57. PubMed ID: 1386976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
    Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
    Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
    Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1891-903. PubMed ID: 1387775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
    Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
    J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
    Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
    J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
    Roila F
    Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodology and assessment in clinical anti-emetic research: a meta-analysis of outcome parameters.
    Morrow GR
    Br J Cancer Suppl; 1992 Dec; 19():S38-41. PubMed ID: 1467200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails.
    Hu W; Fang J; Nie J; Dai L; Chen X; Zhang J; Ma X; Tian G; Han J
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1129-36. PubMed ID: 24748417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 560.